Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99,605,545
-
Number of holders
-
481
-
Total 13F shares, excl. options
-
90,892,702
-
Shares change
-
+1,062,129
-
Total reported value, excl. options
-
$9,194,138,307
-
Value change
-
+$67,286,199
-
Put/Call ratio
-
1.69%
-
Number of buys
-
248
-
Number of sells
-
-249
-
Price
-
$101.22
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q1 2023
576 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q1 2023.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 481 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 90,892,702 shares
of 99,605,545 outstanding shares and own 91.25% of the company stock.
Largest 10 shareholders include BlackRock Inc. (13,466,650 shares), VANGUARD GROUP INC (9,597,532 shares), STATE STREET CORP (3,799,915 shares), Bellevue Group AG (2,613,300 shares), JPMORGAN CHASE & CO (2,156,009 shares), JANUS HENDERSON GROUP PLC (1,994,521 shares), RENAISSANCE TECHNOLOGIES LLC (1,947,064 shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1,744,714 shares), MORGAN STANLEY (1,654,893 shares), and Bank of New York Mellon Corp (1,652,009 shares).
This table shows the top 481 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.